1. Home
  2. NRIX vs USPH Comparison

NRIX vs USPH Comparison

Compare NRIX & USPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • USPH
  • Stock Information
  • Founded
  • NRIX 2009
  • USPH 1990
  • Country
  • NRIX United States
  • USPH United States
  • Employees
  • NRIX N/A
  • USPH N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • USPH Medical/Nursing Services
  • Sector
  • NRIX Health Care
  • USPH Health Care
  • Exchange
  • NRIX Nasdaq
  • USPH Nasdaq
  • Market Cap
  • NRIX 1.3B
  • USPH 1.4B
  • IPO Year
  • NRIX 2020
  • USPH 1992
  • Fundamental
  • Price
  • NRIX $19.83
  • USPH $91.24
  • Analyst Decision
  • NRIX Strong Buy
  • USPH Strong Buy
  • Analyst Count
  • NRIX 17
  • USPH 4
  • Target Price
  • NRIX $30.29
  • USPH $114.00
  • AVG Volume (30 Days)
  • NRIX 988.4K
  • USPH 113.5K
  • Earning Date
  • NRIX 02-13-2025
  • USPH 11-05-2024
  • Dividend Yield
  • NRIX N/A
  • USPH 1.93%
  • EPS Growth
  • NRIX N/A
  • USPH N/A
  • EPS
  • NRIX N/A
  • USPH 0.94
  • Revenue
  • NRIX $56,424,000.00
  • USPH $639,062,000.00
  • Revenue This Year
  • NRIX N/A
  • USPH $13.49
  • Revenue Next Year
  • NRIX $3.79
  • USPH $12.33
  • P/E Ratio
  • NRIX N/A
  • USPH $97.40
  • Revenue Growth
  • NRIX N/A
  • USPH 9.20
  • 52 Week Low
  • NRIX $7.65
  • USPH $76.18
  • 52 Week High
  • NRIX $29.56
  • USPH $113.63
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 38.42
  • USPH 41.99
  • Support Level
  • NRIX $19.38
  • USPH $92.10
  • Resistance Level
  • NRIX $21.67
  • USPH $98.07
  • Average True Range (ATR)
  • NRIX 1.34
  • USPH 2.66
  • MACD
  • NRIX 0.00
  • USPH -1.07
  • Stochastic Oscillator
  • NRIX 12.61
  • USPH 13.24

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

About USPH U.S. Physical Therapy Inc.

US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal sources of payment for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.

Share on Social Networks: